Skip to main content

Table 4 Clinical scores. Secondary endpoints

From: High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study

 

W0

W12

W24

W36

W48

Absolute change between W0 and W48

p-value

MRC

168 (160;177)

175 (164;178)

176 (166;179)

178 (164;180)

176 (166;180)

3 (0; 9)

.037

INCAT

6 (4;8)

5 (2;10)

4 (2;7)

4 (2;7)

3 (1;7)

-3 (-3; 0)

.014

Timed 10-m walk (s)

8 (7;12)

7 (6;9)

8 (7;10)

8 (6;12)

7 (6;12)

-1 (-2; 0)

.178

6-min walking distance (m)

375 (293;474)

419 (315;470)

442 (293;489)

427 (285;489)

469 (278;506)

69 (10;104)

 < .001

ONLS

3 (2;4)

2 (2;3)

3 (2;3)

3 (2;4)

2 (1;4)

-1 (-1;1)

.264

  1. Missing data at W48 were imputed with the LOCF method (W36 for patient #04, CIDP group). The P-value was calculated with the Wilcoxon signed rank test. The results are expressed as median (IQR) calculated in all patients (n = 15)